Last reviewed · How we verify
NCT03681613
Exercise Therapy in Combination With Central Nervous System-targeted Treatment for Osteoarthritis
NA trial testing NEMEX program combined with a CNS-focused protocol in Osteoarthritis in 121 participants. Completed in 30 August 2022.
30 August 2022
Quick facts
| Lead sponsor | University of Valencia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 121 |
| Start date | 7 January 2019 |
| Primary completion | 30 August 2022 |
| Estimated completion | 30 August 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- NEMEX program combined with a CNS-focused protocol
- NEMEX program
Conditions studied
- Osteoarthritis — all drugs for Osteoarthritis →
- Osteo Arthritis Knee — all drugs for Osteo Arthritis Knee →
Sponsor
University of Valencia
Who can join
41 and older, any sex, with Osteoarthritis or Osteo Arthritis Knee. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigate if exercise therapy comprising the NEMEX program in combination with a CNS-targeted treatment using GMI and SDT is superior to exercise therapy alone in improving self-reported pain, function, quality of life and objective measures related to hyperexcitability of the CNS (e.g. central sensitization) in people with KOA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03681613
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Osteoarthritis
Currently open trials in the same condition.
- NCT07404891 — Clinical Trial on the Efficacy and Safety of ALT001 in Osteoarthritis · NA · recruiting
- NCT07118501 — A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System · recruiting
- NCT06631638 — EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN)) · NA · recruiting
- NCT07198750 — "Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis" · NA · recruiting
- NCT07006714 — Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA) · Phase 4 · active not recruiting
Other University of Valencia trials
Trials by the same sponsor.
- NCT07509281 — Peri-implant Tissues Changes for Different Abutment Shapes and Heights · NA · not yet recruiting
- NCT07535528 — Implant Placement Depth and Peri-Implant Tissue Outcomes · NA · not yet recruiting
- NCT07471555 — Vascular Access and Intraosseus · NA · enrolling by invitation
- NCT07463066 — Long-Term Effectiveness of Pain Neuroscience Education in Women With Genito-Pelvic Pain/Penetration Disorder. · not yet recruiting
- NCT07419399 — Acute Effects of Radiofrequency Diathermy in Postpartum Women With Diastasis Abdominis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03681613 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Valencia
- Last refreshed: 23 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03681613.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing